Bill > HF3054

This bill modifies prescription drug transparency provisions in Minnesota, primarily focusing on expanding and refining reporting requirements for various entities involved in the prescription drug supply chain. The bill amends existing statutes to require more detailed reporting from 340B covered entities (healthcare organizations that can purchase drugs at discounted prices), manufacturers, pharmacies, pharmacy benefit managers (PBMs), and wholesale drug distributors. Key changes include requiring more granular information about drug prices, costs, rebates, and sales, such as specifying the year a drug was introduced, detailed cost breakdowns, and sales volumes. The bill introduces more comprehensive reporting for prescription drugs that the state determines to have substantial public interest, with the commissioner of health empowered to select up to 500 drugs quarterly for enhanced scrutiny. Reporting entities must submit detailed information within 60 days of notification, including specifics about drug pricing, acquisition costs, rebates, and profit margins. The bill also adjusts registration requirements, pushing the effective date for entity registration to January 1, 2026, and mandates annual updates. The overall goal appears to be increasing transparency in prescription drug pricing and creating a more comprehensive understanding of the factors influencing drug costs in Minnesota.

Health and Social Services

https://www.revisor.mn.gov/bills/bill.php?b=House&f=HF3054&ssn=0&y=2025